{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-25-000081","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.828804+00:00","generated_at":"2026-05-17T05:22:31.235442+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AnaptysBio to split into two public companies by end of 2026; royalty assets separate from biopharma","bullets":["CEO Daniel Faga expected to lead Biopharma Co; Royalty Co holds Jemperli (GSK) and imsidolimab (Vanda) royalties.","Jemperli royalties tiered: 8% up to $1B sales, 12% $1-1.5B, 20% $1.5-2.5B, 25% above $2.5B; GSK peak sales guide >£2B.","Sagard monetization capped at $600M; expected paydown mid-2027 to Q2 2028.","Biopharma Co pipeline: rosnilimab (Phase 2b RA, Phase 2 UC top-line Nov/Dec 2025), ANB033 (celiac Ph1b), ANB101 (Ph1a).","Separation targeted by year-end 2026; taxable but minimizing taxes; subject to board and SEC approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-25-000081","json":"https://secwatch.observer/filing/0001370053-25-000081.json","markdown":"https://secwatch.observer/filing/0001370053-25-000081.md","text":"https://secwatch.observer/filing/0001370053-25-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000081/0001370053-25-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000081/anab-20250929.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:22:31.235442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}